This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Digging into the phase 1b clinical trial data of AB-1005 in patients with Parkinson's Disease.
Ticker(s): BAYN.XSWX, AskBioWho's the expert?
Institution: Neurological Consultants
- General neurologist who sees 100 patients with Parkinson's Disease
- Works in a suburban multi specialty group
Interview Goalto discuss the current standard of care and the potential of AB-1005, a gene therapy being developed by AskBio and Bayer for the treatment of Parkinson's Disease.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
